These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37989065)

  • 1. An overview: Radiotracers and nano-radiopharmaceuticals for diagnosis of Parkinson's disease.
    Ozolmez N; Silindir-Gunay M; Volkan-Salanci B
    Appl Radiat Isot; 2024 Jan; 203():111110. PubMed ID: 37989065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
    Thobois S; Guillouet S; Broussolle E
    Neurophysiol Clin; 2001 Oct; 31(5):321-40. PubMed ID: 11817273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotracers for imaging of Parkinson's disease.
    Abbasi Gharibkandi N; Hosseinimehr SJ
    Eur J Med Chem; 2019 Mar; 166():75-89. PubMed ID: 30685535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New molecular targets for PET and SPECT imaging in neurodegenerative diseases.
    Benadiba M; Luurtsema G; Wichert-Ana L; Buchpigel CA; Busatto Filho G
    Braz J Psychiatry; 2012 Oct; 34 Suppl 2():S125-36. PubMed ID: 23429844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease and dopamine transporter neuroimaging: a critical review.
    Shih MC; Hoexter MQ; Andrade LA; Bressan RA
    Sao Paulo Med J; 2006 May; 124(3):168-75. PubMed ID: 17119698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective.
    Thobois S; Prange S; Scheiber C; Broussolle E
    Parkinsonism Relat Disord; 2019 Feb; 59():93-100. PubMed ID: 30181086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of SPECT in the diagnosis of Parkinson's disease.
    Emami-Avedon SS; Ichise M; Lang AE
    Can Assoc Radiol J; 2000 Jun; 51(3):189-96. PubMed ID: 10914086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Prange S; Hermier M; Danaila T; Laurencin C; Thobois S
    Presse Med; 2017 Mar; 46(2 Pt 1):202-209. PubMed ID: 28040345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.
    Neishi H; Ikawa M; Okazawa H; Tsujikawa T; Arishima H; Kikuta KI; Yoneda M
    Eur Neurol; 2017; 78(3-4):161-168. PubMed ID: 28848099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease.
    de Natale ER; Niccolini F; Wilson H; Politis M
    Int Rev Neurobiol; 2018; 141():131-172. PubMed ID: 30314595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease.
    Seibyl J; Jennings D; Tabamo R; Marek K
    Minerva Med; 2005 Oct; 96(5):353-64. PubMed ID: 16227950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments of dopaminergic imaging in Parkinson's disease.
    Varrone A; Halldin C
    Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):68-82. PubMed ID: 22460161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPECT and PET imaging of the dopaminergic system in Parkinson's disease.
    Brücke T; Djamshidian S; Bencsits G; Pirker W; Asenbaum S; Podreka I
    J Neurol; 2000 Sep; 247 Suppl 4():IV/2-7. PubMed ID: 11199811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease.
    Kahraman D; Eggers C; Schicha H; Timmermann L; Schmidt M
    J Neurol; 2012 Feb; 259(2):251-60. PubMed ID: 21750954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research progress in the early diagnosis of Parkinson's disease.
    Xie L; Hu L
    Neurol Sci; 2022 Nov; 43(11):6225-6231. PubMed ID: 35948779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET/SPECT imaging agents for neurodegenerative diseases.
    Zhu L; Ploessl K; Kung HF
    Chem Soc Rev; 2014 Oct; 43(19):6683-91. PubMed ID: 24676152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of neuroimaging in Parkinson's disease.
    Bidesi NSR; Vang Andersen I; Windhorst AD; Shalgunov V; Herth MM
    J Neurochem; 2021 Nov; 159(4):660-689. PubMed ID: 34532856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-head comparison of
    Lee I; Kim JS; Park JY; Byun BH; Park SY; Choi JH; Moon H; Kim JY; Lee KC; Chi DY; Kim KM; Lim I; Kang JH; Ahn SH; Kim BI; Ha JH; Lim SM
    Synapse; 2018 Jul; 72(7):e22032. PubMed ID: 29486515
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging.
    Huang WS; Lin SZ; Lin JC; Wey SP; Ting G; Liu RS
    J Nucl Med; 2001 Sep; 42(9):1303-8. PubMed ID: 11535717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study.
    Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O
    Nucl Med Commun; 2006 Apr; 27(4):381-6. PubMed ID: 16531926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.